Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T followed by allo-HSCT for R/R Multiple Myeloma
NCT06913179Phase 1Not yet recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of ISIKOK-19 in multiple myeloma (MM), sponsored by Xuzhou Medical University. Primary endpoint: Overall Response Rate at 24 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ISIKOK-19
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06913179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913179.